Guidance and quality standards awaiting development | Guidance

Showing 371 to 380 of 389

Guidance and quality standards awaiting development
Title	Type
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vertebral body tethering for idiopathic scoliosis in children and young people	HealthTech guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalities	Quality standard
VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance